UK contract research organization hVIVO (AIM: HVO) is gearing up to test an inhaled antiviral candidate, IN-002, for ...

Clinical trials company Hvivo has completed its first acquisition, buying two research units from German group CRS for €10 ...

ILiAD Biotechnologies, LLC, a biotech company developing BPZE1, the most advanced next generation intranasal pertussis ...

Condition affects about 16m people per year, and accounts for about 160,700 deaths in children younger than five ...

LONDON - Shionogi & Co., Ltd. (TYO:4507) has reported positive outcomes from its Phase 2a human challenge trial for an ...

(Alliance News) - hVIVO PLC on Monday said it has signed a contract with Inhalon Biopharma Inc to test its antiviral candidate to treat respiratory syncytial virus. The London-based contract research ...

Hvivo paid £10 million in cash for the takeover of CRS, a German clinical trial firm with two research units, marking the ...

Pharmaceutical services firm hVivo, formerly Open Orphan, has acquired two clinical trial units in Germany from CRS Clinical ...

LONDON - hVIVO plc, a leading early-stage Contract Research Organisation (CRO) known for its human challenge clinical trials, has acquired two Clinical Research Units (CRUs) from CRS Clinical ...

VIVO, a fast-growing early-stage German contract research organization (CRO) has acquired two clinical research units from Clinical Research Services (CRS), in Mannheim and Kiel, Germany, for a total ...

(Sharecast News) - hVIVO announced on Monday that it has signed a letter of intent with ILiAD Biotechnologies to conduct a pivotal phase three human challenge trial for ILiAD's lead whooping cough ...